Growth hormone and insulin during oxandrolone therapy of stunting

Abstract

Department of Medicine and Medical Center Hospitals of the University of Pittsburgh, Shadyside Hospital of Pittsburgh, and Department of Anatomy of Indiana UniversityStunting, with increases in serum growth hormone (GH) levels in response to insulin-induced hypoglycemia or to arginine, has been described in children with constitutional growth retardation. 6 , 7, 21, 25, 28, 30, 31 Supported by grants from tbe John A. Hartford Foundation, Inc., the Western Pennsylvania Arthritis Foundation, the Charles A. Locke Educational and Charitable Trust of the Pittsburgh Foundation, and the Department of Health, Education, and Welfare.Received for publication May 8, 1968. Accepted for publication June 18, 1968.Our data indicate that levels of serum GH observed during the intravenous tolbutamide test in such individuals are about the same as those recorded in normal children. Also, the peak GH responses to tolbutamide and to arginine decrease during therapy with a protein anabolie steroid with rela- 749

Effect of low dose oxandrolone and testosterone treatment on the pituitary‐testicular and GH axes in boys with constitutional delay of growth and puberty

“…Data from provocation tests are also conflicting. A reduction in peak GH response to tolbutamide or arginine (Danowski et al, 1968), an increased GH response to GRF (Loche et al, 1986), and no change in GH response to GRF, arginine or sleep in prepubertal boys but an increase in GH secreted in sleep (but not after arginine or GRF) in pubertal boys (Clayton et al, 1988) have all been reported after oxandrolone administration. Ulloa-Aguirre et al (1990) studied younger boys with lower body mass indices than those studied by ourselves or by Link et al (1986) and the twice daily administration of oxandrolone in higher dosage/kg body weight, continued during sampling, may also have had a more sustained androgenic effect.…”